Zelira Therapeutics Limited (ZLD.AX)
AUD 0.35
(0.0%)
AUD 0.35
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 5.94 Million AUD | 41.74% |
| 2023 | 4.19 Million AUD | -45.49% |
| 2022 | 7.69 Million AUD | -19.91% |
| 2021 | 9.61 Million AUD | 27.1% |
| 2020 | 7.56 Million AUD | 78.93% |
| 2019 | 4.22 Million AUD | 50.13% |
| 2018 | 2.81 Million AUD | 9.54% |
| 2017 | 2.57 Million AUD | 193.28% |
| 2016 | 876.42 Thousand AUD | 106.79% |
| 2015 | 423.82 Thousand AUD | 43.58% |
| 2014 | 295.17 Thousand AUD | -8.35% |
| 2013 | 322.06 Thousand AUD | -48.93% |
| 2012 | 630.62 Thousand AUD | 36.18% |
| 2011 | 463.08 Thousand AUD | -59.74% |
| 2010 | 1.15 Million AUD | -37.98% |
| 2009 | 1.85 Million AUD | 280.06% |
| 2008 | 487.99 Thousand AUD | -98.95% |
| 2007 | 46.55 Million AUD | 3352.39% |
| 2006 | 1.34 Million AUD | 56.67% |
| 2005 | 860.64 Thousand AUD | -17.05% |
| 2004 | 1.03 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 2.55 Million AUD | 0.0% |
| 2024 Q2 | 2.23 Million AUD | 0.0% |
| 2024 FY | 4.78 Million AUD | 14.01% |
| 2023 Q4 | 2.73 Million AUD | 0.0% |
| 2023 FY | 4.19 Million AUD | -45.49% |
| 2023 Q2 | 1.46 Million AUD | 0.0% |
| 2022 FY | 7.69 Million AUD | -19.91% |
| 2022 Q2 | 3.62 Million AUD | 0.0% |
| 2022 Q4 | 4.06 Million AUD | 0.0% |
| 2021 Q2 | 4.9 Million AUD | 0.0% |
| 2021 FY | 9.61 Million AUD | 27.1% |
| 2021 Q4 | 4.71 Million AUD | 0.0% |
| 2020 Q4 | 4.22 Million AUD | 0.0% |
| 2020 Q2 | 3.33 Million AUD | 0.0% |
| 2020 FY | 7.56 Million AUD | 78.93% |
| 2019 Q4 | 2.32 Million AUD | 0.0% |
| 2019 FY | 4.22 Million AUD | 50.13% |
| 2019 Q2 | 2.11 Million AUD | 0.0% |
| 2018 Q4 | 1.52 Million AUD | 0.0% |
| 2018 FY | 2.81 Million AUD | 9.54% |
| 2018 Q2 | 653.17 Thousand AUD | 0.0% |
| 2017 FY | 2.57 Million AUD | 193.28% |
| 2017 Q4 | 1.26 Million AUD | 0.0% |
| 2017 Q2 | 5.05 Million AUD | 0.0% |
| 2016 Q4 | 481.13 Thousand AUD | 358.79% |
| 2016 Q1 | 54.02 Thousand AUD | 0.0% |
| 2016 Q2 | 91.97 Thousand AUD | 70.27% |
| 2016 Q3 | 104.87 Thousand AUD | 14.02% |
| 2016 FY | 876.42 Thousand AUD | 106.79% |
| 2015 Q3 | 54.02 Thousand AUD | 0.0% |
| 2015 Q1 | 28.71 Thousand AUD | 0.0% |
| 2015 Q4 | 54.02 Thousand AUD | 0.0% |
| 2015 Q2 | 54.02 Thousand AUD | 88.16% |
| 2015 FY | 423.82 Thousand AUD | 43.58% |
| 2014 Q1 | 25.57 Thousand AUD | 0.0% |
| 2014 Q2 | 28.71 Thousand AUD | 12.28% |
| 2014 Q3 | 28.71 Thousand AUD | 0.0% |
| 2014 Q4 | 28.71 Thousand AUD | 0.0% |
| 2014 FY | 295.17 Thousand AUD | -8.35% |
| 2013 Q3 | 25.57 Thousand AUD | 0.0% |
| 2013 Q1 | 43.33 Thousand AUD | 0.0% |
| 2013 Q2 | 25.57 Thousand AUD | -40.99% |
| 2013 FY | 322.06 Thousand AUD | -48.93% |
| 2013 Q4 | 25.57 Thousand AUD | 0.0% |
| 2012 FY | 630.62 Thousand AUD | 36.18% |
| 2012 Q3 | 43.33 Thousand AUD | 0.0% |
| 2012 Q2 | 43.33 Thousand AUD | -24.35% |
| 2012 Q1 | 57.27 Thousand AUD | 0.0% |
| 2012 Q4 | 43.33 Thousand AUD | 0.0% |
| 2011 Q4 | 57.27 Thousand AUD | 0.0% |
| 2011 Q3 | 57.27 Thousand AUD | 0.0% |
| 2011 FY | 463.08 Thousand AUD | -59.74% |
| 2011 Q2 | 57.27 Thousand AUD | -64.36% |
| 2011 Q1 | 160.69 Thousand AUD | 0.0% |
| 2010 Q4 | 160.69 Thousand AUD | 0.0% |
| 2010 Q3 | 160.69 Thousand AUD | 0.0% |
| 2010 FY | 1.15 Million AUD | -37.98% |
| 2010 Q2 | 160.69 Thousand AUD | -51.69% |
| 2010 Q1 | 332.63 Thousand AUD | 0.0% |
| 2009 Q2 | 332.63 Thousand AUD | 550.65% |
| 2009 Q1 | 51.12 Thousand AUD | 0.0% |
| 2009 Q4 | 332.63 Thousand AUD | 0.0% |
| 2009 FY | 1.85 Million AUD | 280.06% |
| 2009 Q3 | 332.63 Thousand AUD | 0.0% |
| 2008 FY | 487.99 Thousand AUD | -98.95% |
| 2008 Q4 | 51.12 Thousand AUD | 0.0% |
| 2008 Q3 | 51.12 Thousand AUD | 0.0% |
| 2008 Q1 | 10.55 Million AUD | 0.0% |
| 2008 Q2 | 51.12 Thousand AUD | -99.52% |
| 2007 FY | 46.55 Million AUD | 3352.39% |
| 2007 Q1 | 167.4 Thousand AUD | 0.0% |
| 2007 Q2 | 10.55 Million AUD | 6202.14% |
| 2007 Q3 | 10.55 Million AUD | 0.0% |
| 2007 Q4 | 10.55 Million AUD | 0.0% |
| 2006 FY | 1.34 Million AUD | 56.67% |
| 2006 Q2 | 167.4 Thousand AUD | 61.01% |
| 2006 Q3 | 167.4 Thousand AUD | 0.0% |
| 2006 Q1 | 103.97 Thousand AUD | 0.0% |
| 2006 Q4 | 167.4 Thousand AUD | 0.0% |
| 2005 Q2 | 103.97 Thousand AUD | -45.65% |
| 2005 Q1 | 191.3 Thousand AUD | 0.0% |
| 2005 Q4 | 103.97 Thousand AUD | 0.0% |
| 2005 Q3 | 103.97 Thousand AUD | 0.0% |
| 2005 FY | 860.64 Thousand AUD | -17.05% |
| 2004 Q4 | 191.3 Thousand AUD | 0.0% |
| 2004 FY | 1.03 Million AUD | 0.0% |
| 2004 Q3 | 191.3 Thousand AUD | 0.0% |
| 2004 Q2 | 191.3 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AdAlta Limited | 6.76 Million AUD | 12.128% |
| Acrux Limited | 8.55 Million AUD | 30.427% |
| Actinogen Medical Limited | 22.77 Million AUD | 73.876% |
| AnteoTech Limited | 12.18 Million AUD | 51.19% |
| Argenica Therapeutics Limited | 8.26 Million AUD | 28.064% |
| Arovella Therapeutics Limited | 10.78 Million AUD | 44.846% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -737.563% |
| Alterity Therapeutics Limited | 23.4 Million AUD | 74.586% |
| Amplia Therapeutics Limited | 8.43 Million AUD | 29.484% |
| Avecho Biotechnology Limited | 4.54 Million AUD | -30.869% |
| Bio-Gene Technology Limited | 2.76 Million AUD | -115.447% |
| Biome Australia Limited | 7.91 Million AUD | 24.809% |
| Biotron Limited | 5.11 Million AUD | -16.394% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -888.421% |
| BTC Health Limited | -1.03 Million AUD | 672.563% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | 69.907% |
| CSL Limited | 7.56 Billion AUD | 99.921% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 89.436% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 80.993% |
| Cynata Therapeutics Limited | 11.12 Million AUD | 46.523% |
| Dimerix Limited | 25.64 Million AUD | 76.803% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | 84.969% |
| Hexima Limited | 1 Million AUD | -489.692% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | -44.194% |
| Immuron Limited | 9.13 Million AUD | 34.903% |
| Immutep Limited | 42.87 Million AUD | 86.126% |
| Imugene Limited | 135.09 Million AUD | 95.597% |
| Invex Therapeutics Ltd | 3.34 Million AUD | -77.786% |
| Memphasys Limited | 3.67 Million AUD | -61.716% |
| Nanollose Limited | 12.5 Thousand AUD | -47484.305% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | 81.807% |
| Noxopharm Limited | 7 Million AUD | 15.024% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -202.689% |
| Nyrada Inc. | 4.55 Million AUD | -30.588% |
| Orthocell Limited | 15.36 Million AUD | 61.297% |
| PharmAust Limited | 6.65 Million AUD | 10.643% |
| Patrys Limited | 4.93 Million AUD | -20.578% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 90.863% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -566.767% |
| Prescient Therapeutics Limited | 10.89 Million AUD | 45.42% |
| PYC Therapeutics Limited | 60.91 Million AUD | 90.235% |
| Race Oncology Limited | 14.77 Million AUD | 59.727% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -1887.954% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | 72.568% |
| Starpharma Holdings Limited | 22.81 Million AUD | 73.928% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 97.791% |
| Tissue Repair Ltd | 6.66 Million AUD | 10.774% |